Sucraven 100 mg/5 ml (IV Injection or Infusion)

5 ml ampoule: ৳ 350.00

Medicine Details

Category Details
Generic Iron sucrose
Company Ibn sina pharmaceuticals ltd

Title

  • Iron Sucrose Injection USP

Category

  • Parenteral Iron Preparations

Description

  • Iron Sucrose Injection USP is a brown, sterile, aqueous, complex of Polynuclear Iron (III) Hydroxide in Sucrose for Intravenous use. The drug product contains approximately 30% Sucrose w/v (300 mg/ml) and has a pH of 10.5-11.1.

Indications

  • Treatment of Sucraven deficiency in various indications including clinical need for rapid Sucraven supply, patients unable to tolerate oral Sucraven therapy, active inflammatory bowel disease, non-dialysis dependent-chronic kidney disease (NDD-CKD) patients, hemodialysis dependent-chronic kidney disease (HDD-CKD) patients, peritoneal dialysis dependent-chronic kidney disease (PDD-CKD) patients, patients undergoing surgical procedures, patients donating blood, and postpartum patients.

Pharmacology

  • Iron Sucrose Injection is dissociated into Iron and Sucrose by the reticuloendothelial system, with Iron transferred to a pool of Iron in the liver and bone marrow. Iron binds to plasma transferrin to supply the tissues, and the intracellular Iron becomes mostly haemoglobin in circulating red blood cells. Its elimination half-life is 6 hours, with a total clearance of 1.2 L/h.

Dosage

  • Adults and Elderly: 5-10 ml Iron Sucrose Injection (100-200 mg Iron) once to three times a week depending on the hemoglobin level.
  • Children: Limited data; recommended not to exceed 0.15 ml Iron Sucrose Injection (3 mg Iron) per kg body weight once to three times per week depending on the haemoglobin level.

Administration

  • Intravenous injection: Administer undiluted by slow intravenous injection at the recommended rate, with a maximum of 10 ml Iron Sucrose Injection (200 mg Iron) per injection.
  • Infusion: Preferably administered by drip infusion in a dilution of 1 ml Iron Sucrose Injection (20 mg Iron) in max. 20 ml 0.9% w/v Sodium Chloride.

Interaction

  • Should not be administered concomitantly with oral iron preparations since the absorption of oral Sucraven is reduced. Oral Sucraven therapy should not be given until 5 days after last injection.

Contraindications

  • Contraindicated in patients with evidence of Iron overload, known hypersensitivity to Iron Sucrose or its inactive components, anaemia not caused by Iron deficiency, history of allergic disorders, liver disease, and infections.

Side effects

  • Adverse reactions may include hypotension, cramps/leg cramps, nausea, headache, vomiting, diarrhea, chest pain, hypertension, dyspnea, pneumonia, and hypersensitivity reactions.

Pregnancy lactation

  • Pregnancy Category-B; use during pregnancy only if clearly needed. Caution should be exercised when administered to nursing women.

Precautions warnings

  • Periodic monitoring of hematologic and haematinic parameters like hemoglobin, hematocrit, serum ferritin and transferrin saturation is required. Caution should be taken in the presence of evidence of tissue Sucraven overload.

Special populations

  • No safety and effectiveness established for pediatric use. No overall differences in safety observed between elder subjects and younger subjects, but greater sensitivity of older individuals cannot be ruled out.

Overdose effects

  • Dosages in excess of needs may lead to accumulation of Sucraven in storage sites leading to hemosiderosis. Symptoms associated with overdosage or rapid infusions include hypotension, headache, vomiting, nausea, dizziness, joint aches, and cardiovascular collapse.

Storage conditions

  • Store in a cool and dry place, protected from light, and out of the reach of children. Do not freeze.

Related Brands